GDC-1971 (formerly RLY-1971)
Undisclosed
Phase 1Active (Partner-led)
Key Facts
About Relay Therapeutics
Relay Therapeutics is a clinical-stage biotech company founded in 2016 with a mission to transform drug discovery by targeting protein dynamics. Its core achievement is the development of the Dynamo™ platform, which integrates computational and experimental biology to identify novel therapeutic mechanisms. The company's strategy is to leverage this platform to create highly selective small molecule drugs for precision oncology, with its lead candidate, RLY-4008, in pivotal development for FGFR2-altered cancers. Relay is publicly traded and aims to validate its motion-based drug design approach through clinical success.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |